ES486992A1 - Un procedimiento para la preparacion de un derivado de car- boestirilo - Google Patents

Un procedimiento para la preparacion de un derivado de car- boestirilo

Info

Publication number
ES486992A1
ES486992A1 ES486992A ES486992A ES486992A1 ES 486992 A1 ES486992 A1 ES 486992A1 ES 486992 A ES486992 A ES 486992A ES 486992 A ES486992 A ES 486992A ES 486992 A1 ES486992 A1 ES 486992A1
Authority
ES
Spain
Prior art keywords
group
carbon atoms
hydrogen atom
alkyl
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES486992A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of ES486992A1 publication Critical patent/ES486992A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En lo que se refiere a las actividades de control nervioso central, los compuestos de la presente invención se caracterizan porque presentan fuertes actividades de control sobre la actitud de lucha de ratones que han permanecido aislados durante largos periodos de tiempo. Así. En comparación con el Diazepam, que es un compuesto con una reconocida elevada actividad de este tipo, los compuestos de la presente invención tiene un importante efecto de control sobre la actitud de lucha de ratones. Por tanto, los compuestos presentes son bastantes útiles particularmente como sedantes, fármacos anti-ansiedad, y fármacos anti-psicosis maniaco depresiva. Además los compuestos de la presente invención aumentan fuertemente la anestesia y el sueño cuando se utilizan en combinación con anestésicos e hipnóticos.
ES486992A 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo Expired ES486992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3778378A JPS54130587A (en) 1978-03-30 1978-03-30 Carbostyryl derivative

Publications (1)

Publication Number Publication Date
ES486992A1 true ES486992A1 (es) 1980-10-01

Family

ID=12507080

Family Applications (4)

Application Number Title Priority Date Filing Date
ES479134A Expired ES479134A1 (es) 1978-03-30 1979-03-30 Un procedimiento para la preparacion de un derivado de car- boestirilo.
ES486990A Expired ES486990A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486991A Expired ES486991A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486992A Expired ES486992A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES479134A Expired ES479134A1 (es) 1978-03-30 1979-03-30 Un procedimiento para la preparacion de un derivado de car- boestirilo.
ES486990A Expired ES486990A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo
ES486991A Expired ES486991A1 (es) 1978-03-30 1979-12-17 Un procedimiento para la preparacion de un derivado de car- boestirilo

Country Status (21)

Country Link
US (2) US4734416A (es)
JP (1) JPS54130587A (es)
AT (1) AT376432B (es)
AU (1) AU515531B2 (es)
BE (1) BE875174A (es)
CA (1) CA1117110A (es)
CH (2) CH641455A5 (es)
DE (2) DE2953723C2 (es)
DK (1) DK158225C (es)
ES (4) ES479134A1 (es)
FI (1) FI70704C (es)
FR (1) FR2421174A1 (es)
GB (1) GB2017701B (es)
IT (1) IT1119284B (es)
MX (1) MX5862E (es)
NL (1) NL183189C (es)
NO (1) NO151321C (es)
PT (1) PT69422A (es)
SE (1) SE434945B (es)
SU (2) SU1140687A3 (es)
ZA (1) ZA791516B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
JPS6129331A (ja) * 1985-03-13 1986-02-10 アラ−ガン・ハンフリ− 検眼装置
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
DK397387A (da) * 1986-07-31 1988-02-01 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf samt fremgangsmaade til fremstilling af saadanne forbindelser
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PE20030445A1 (es) 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
BR0305500A (pt) * 2003-01-09 2004-11-03 Otsuka Pharma Co Ltd Processo para preparar aripiprazol
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
AU2004265243A1 (en) * 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c receptor associated diseases
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
PL1613598T3 (pl) * 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
CA2555289A1 (en) * 2004-02-05 2005-08-25 Ben-Zion Dolitzky Process for preparing aripiprazole
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
CN102627603A (zh) * 2004-11-18 2012-08-08 斯索恩有限公司 制备结晶阿立哌唑的方法
EP1812396A1 (en) * 2004-11-18 2007-08-01 Synthon B.V. Crystalline aripiprazole solvates
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
EP1686126A1 (en) * 2005-01-27 2006-08-02 Sandoz AG Salts of aripiprazole
JP5426828B2 (ja) * 2005-01-27 2014-02-26 サンド・アクチエンゲゼルシヤフト アリピプラゾールの塩
CA2600542A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
TW200800202A (en) * 2005-12-22 2008-01-01 Teva Pharma Processes for reducing particle size of aripiprazole
US20090054455A1 (en) * 2006-02-03 2009-02-26 Dr. Reddy's Laboratories Ltd. Aripiprazole co-crystals
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
EP1880714A1 (en) * 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) * 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US8039621B2 (en) * 2006-10-24 2011-10-18 Cambrex Charles City, Inc. Process for preparing anhydrous Aripirazole type I
ATE515554T1 (de) * 2006-12-04 2011-07-15 Merck Patent Gmbh Furochromanderivate
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
BRPI0815382A2 (pt) * 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
ATE482691T1 (de) 2008-01-23 2010-10-15 Helm Ag Amorphes aripiprazol und verfahren zu seiner herstellung
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
BRPI0912362A2 (pt) * 2008-05-09 2015-10-06 Univ Emory antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
SG178938A1 (en) 2009-09-11 2012-04-27 Otsuka Pharma Co Ltd Therapeutic agent for chronic pain
WO2011030213A1 (en) 2009-09-14 2011-03-17 Jubilant Organosys Limited Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP4327872A3 (en) * 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2012131451A1 (en) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Process for producing aripiprazole in anhydrous type i crystals
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9504682B2 (en) * 2012-08-21 2016-11-29 Janssen Pharmaceutica Nv Haptens of aripiprazole
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
ES2963237A1 (es) * 2022-08-25 2024-03-25 Consejo Superior Investigacion Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA801037A (en) * 1968-12-10 Regnier Gilbert Procede de preparation de nouveaux derives du piperazino-phenylethanol
GB1021522A (en) * 1963-05-10 1966-03-02 Ici Ltd 2-quinolone derivatives
GB1075156A (en) * 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
NL131192C (es) * 1965-06-16
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3703522A (en) * 1967-03-30 1972-11-21 Mcneilab Inc Carbostyril derivatives
US3706749A (en) * 1967-03-30 1972-12-19 Mcneilab Inc N-acyl carbostyrils
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
CH523899A (de) * 1968-07-05 1972-06-15 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
BE884459Q (fr) * 1971-05-14 1981-01-26 Boehringer Mannheim Gmbh Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation
DE2335432A1 (de) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
JPS517672B2 (es) * 1972-04-13 1976-03-10
US4256890A (en) * 1972-09-14 1981-03-17 Otsukapharmaceutical Co., Ltd. 3,4-Dihydrocarbostyril derivatives and process for producing the same
DE2354145A1 (de) * 1972-11-02 1974-05-16 Sandoz Ag Chinazolin-2(lh)-one und verfahren zu ihrer herstellung
DE2334009A1 (de) * 1973-07-04 1975-01-23 Boehringer Mannheim Gmbh Purin-derivate sowie verfahren zu ihrer herstellung
US4026895A (en) * 1973-09-08 1977-05-31 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4083853A (en) * 1973-09-08 1978-04-11 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
GB1451900A (en) * 1973-10-30 1976-10-06 Sandoz Ltd Quinolin-2-1h-ones
JPS5089376A (es) * 1973-12-19 1975-07-17
US4032528A (en) * 1974-03-25 1977-06-28 Sandoz, Inc. 1,4-substituted-quinolin-2(1h)-ones as cns agents
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2631317A1 (de) * 1975-07-23 1977-02-17 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
ES456325A1 (es) * 1976-02-27 1978-05-01 Sandoz Ag Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
CH619453A5 (es) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
US4210753A (en) * 1976-03-17 1980-07-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4110449A (en) * 1977-05-23 1978-08-29 E. R. Squibb & Sons, Inc. 2-substituted benzisothiazol-3-ones
US4166116A (en) * 1977-11-11 1979-08-28 Canadian Patents And Development Limited Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
GB2017701A (en) 1979-10-10
BE875174A (fr) 1979-10-01
DK158225C (da) 1990-09-17
AU515531B2 (en) 1981-04-09
FR2421174B1 (es) 1982-11-19
SU1232144A3 (ru) 1986-05-15
SE7902794L (sv) 1979-10-01
NO791049L (no) 1979-10-02
DE2953723C2 (de) 1989-01-12
NO151321B (no) 1984-12-10
DK128679A (da) 1979-10-26
CH641350A5 (de) 1984-02-29
FI791034A (fi) 1979-10-01
PT69422A (en) 1979-04-01
AT376432B (de) 1984-11-26
FI70704C (fi) 1986-10-06
US4734416A (en) 1988-03-29
IT7967674A0 (it) 1979-03-30
CH641455A5 (de) 1984-02-29
NL183189C (nl) 1988-08-16
DE2912105A1 (de) 1979-10-11
GB2017701B (en) 1983-03-16
JPS54130587A (en) 1979-10-09
NL7902514A (nl) 1979-10-02
DE2912105C2 (de) 1985-08-29
MX5862E (es) 1984-08-13
SU1140687A3 (ru) 1985-02-15
IT1119284B (it) 1986-03-10
ES486991A1 (es) 1980-10-01
ATA235179A (de) 1984-04-15
US4824840A (en) 1989-04-25
ES479134A1 (es) 1980-06-16
JPS6223750B2 (es) 1987-05-25
FI70704B (fi) 1986-06-26
CA1117110A (en) 1982-01-26
FR2421174A1 (fr) 1979-10-26
ES486990A1 (es) 1980-10-01
ZA791516B (en) 1980-04-30
DK158225B (da) 1990-04-16
SE434945B (sv) 1984-08-27
AU4548079A (en) 1979-10-04
NO151321C (no) 1985-03-20

Similar Documents

Publication Publication Date Title
ES486992A1 (es) Un procedimiento para la preparacion de un derivado de car- boestirilo
ES8306141A1 (es) Un procedimiento para la produccion de un derivado de carbostirilo
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
SE8004783L (sv) Delta?722-1,2,4triazolin-5-on-derivat
ES8400422A1 (es) "procedimiento de preparacion de eteres triciclicos, asi como de sus sales de adicion con un acido mineral u organico terapeuticamente compatible".
ES8200679A1 (es) Un procedimiento para la preparacion de derivados de carboestirilo.
ATE61374T1 (de) Diaminoandrostanderivate.
ES445790A1 (es) Procedimiento para preparar derivados de 3-formilrifamicina sv.
KR900006301A (ko) 1,4-디아자비사이클로[3.2.2]노난의 제조방법
ES8702433A1 (es) Un procedimiento para la preparacion de un compuesto heterociclico sustituido con peptidos.
DE3372095D1 (en) Novel phenylpiperazine derivatives and process for producing the same
MX170732B (es) Composicion de derivados de succinimida y su uso
ES8202818A1 (es) Un procedimiento para preparar derivados de tetrazolilcuma- rina
SE8102690L (sv) Karbostyrilderivat
MY106839A (en) Carboxylate compounds, liquid crystal compositions containing said compounds and liquid crystal elements.
ES8105715A1 (es) Procedimiento de preparar derivados isoquinolinicos
ES479444A1 (es) Un procedimiento para preparar derivados de pirrolidincarbo-xaldehido y piperidicarboxaldehido.
ES8304972A1 (es) Procedimiento de preparar derivados de acido carboxilico quetienen actividad antibacteriana.
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
ES482070A1 (es) Procedimiento de preparacion de un nuevo derivado de isoqui-noleina.
ES471267A1 (es) Procedimiento para la preparacion de alquilo inferior 2-tri-(inferior) alquilsililacetileno-n-carbetoxiglicinatos y ami-no acidos derivados de ellos
ES8206550A1 (es) Un procedimiento para la preparacion de derivados de 2-desoxi-3-5-di-o-alquilcarbonil-5-fluorurina.
ES8705426A1 (es) Un procedimiento para la preparacion de un derivado de piperazina.
ES8504772A1 (es) Un procedimiento para preparar un compuesto de 7-(4-piridil)-1,8-naftiridina.
ES8105300A1 (es) Procedimiento para preparar derivados de benoimidazol